JPMorgan Chase & Co. Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price boosted by JPMorgan Chase & Co. from $55.00 to $58.00 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

OLMA has been the topic of several other research reports. HC Wainwright dropped their price objective on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday. UBS Group began coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price objective for the company. Finally, TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $44.89.

Olema Pharmaceuticals Trading Down 3.1%

NASDAQ:OLMA opened at $14.60 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 8.03. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The stock’s 50-day moving average is $23.56 and its two-hundred day moving average is $18.70. The stock has a market cap of $1.00 billion, a PE ratio of -7.85 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. As a group, equities research analysts forecast that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Activity

In other news, insider David C. Myles sold 51,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the transaction, the insider owned 551,881 shares of the company’s stock, valued at approximately $16,810,295.26. This represents a 8.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 805,501 shares of company stock valued at $23,003,832. Corporate insiders own 16.36% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Titleist Asset Management LLC bought a new position in Olema Pharmaceuticals in the 2nd quarter worth $64,000. Diadema Partners LP lifted its position in Olema Pharmaceuticals by 153.7% during the 2nd quarter. Diadema Partners LP now owns 253,657 shares of the company’s stock worth $1,081,000 after acquiring an additional 153,657 shares during the last quarter. Candriam S.C.A. boosted its holdings in Olema Pharmaceuticals by 46.9% during the third quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock valued at $12,235,000 after acquiring an additional 399,273 shares during the period. Birchview Capital LP bought a new stake in Olema Pharmaceuticals during the second quarter valued at about $571,000. Finally, Kingdon Capital Management L.L.C. acquired a new stake in shares of Olema Pharmaceuticals in the third quarter valued at about $8,361,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Key Stories Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Major price‑target upgrades from big banks: Citigroup raised its target to $62 (buy) and JPMorgan bumped its target to $58 (overweight), signaling outsized upside relative to the current share level and supporting buy‑side interest. Benzinga
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple quarters and extended horizon upgrades (FY2026–FY2030) while keeping a Buy rating and $38 target — this reduces near‑term downside in forecasts and is a supportive fundamental datapoint. MarketBeat
• Positive Sentiment: Recent operational/clinical and earnings headlines have attracted capital: a report notes a $68.7M investor bet tied to a breast cancer drug aimed at a 2027 launch, and coverage noting the stock rallied after better‑than‑expected earnings — both draw attention from momentum and event‑driven investors. Globe and Mail American Banking News
• Neutral Sentiment: Presentation of preclinical data at AACR (palazestrant & OP‑3136) is a nearer‑term scientific catalyst; positive data would be bullish, but upcoming abstracts/presentations are binary and uncertain. Business Insider
• Neutral Sentiment: Technicals show a steep recent pullback (down ~33% in 4 weeks) and the stock is in oversold territory—this could set up a short‑term reversal if selling eases, but it also reflects volatility after the prior run. Zacks
• Neutral Sentiment: Guggenheim trimmed its target slightly (to $38) but maintained a Buy — a modest downgrade of enthusiasm rather than a reversal. Benzinga
• Negative Sentiment: Goldman Sachs cut its target from $38 to $27 (still a Buy), which reduces consensus upside and may weigh on sentiment for more cautious investors; mixed analyst signals increase short‑term volatility. Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.